Medications Literature Review
Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
Munir KM, Davis SN. Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes? Expert Opin Pharmacother. 2018 Jun;19(8):773-777. doi: 10.1080/14656566.2018.1475559. Epub 2018 May 22. PMID: 29788782.
The association between the dosage of SGLT2 inhibitor and weight reduction in T2 Diabetes Patients: A Meta-Analysis
Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, Han X, Ji L. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018 Jan;26(1):70-80.
Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
Ribola FA, Cançado FB, Schoueri JH, De Toni VF, Medeiros VH, Feder D. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):199-211. PMID: 28121337.
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomized controlled trials?
Aroda VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018 Feb;20 Suppl 1:22-33. doi: 10.1111/dom.13162. PMID: 29364586.
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin JI. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. Curr Diab Rep. 2019 Jul 8;19(8):54.doi: 10.1007/s11892-019-1171-0. PMID: 31286271.
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016 Jun 4;12:239-49.
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy
Avogaro, A, Delgado, E, Lingvay, I. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018; 34:e2981.
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomed Pharmacother. 2018 Dec;108:952-962. doi: 10.1016/j.biopha.2018.08.088. Epub 2018 Sep 27. PMID: 30372907.
Tags:
For ProvidersNon-videoMCT2D-RecommendedPublished-Literature